Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances

作者：Mo X D; Zhao X Y; Liu D H; Chen Y H; Xu L P; Zhang X H; Chen H; Han W; Wang Y; Wang F R; Wang J Z; Liu K Y; Huang X J^*

来源：Bone Marrow Transplantation, 2014, 49(8): 1070-1075.

DOI：10.1038/bmt.2014.109

This study aimed to compare the therapeutic effects of single umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical hematopoietic SCT (haplo-HSCT) in childhood hematologic malignances. We enrolled 410 consecutive children who received either single UCBT (n = 37) or haplo-HSCT from a family donor (n = 373) during the same time period. For each UCBT recipient, three recipients matched for year of HSCT, underlying diseases, disease status and the length of follow-up were randomly selected from the haplo-HSCT cohort. Hematopoietic recovery was significantly faster in haplo-HSCT recipients than in UCBT recipients. The incidence of chronic GVHD was significantly higher in haplo-HSCT recipients. The incidence of CMV-related interstitial pneumonia was higher in UCBT recipients. The haplo-HSCT recipients had better 1-year OS (73.0% vs 56.8%, P = 0.048), lower 1-year non-relapse mortality (NRM, 18.0% vs 35.1%, P = 0.026) and lower 2-year NRM rates (19.9% vs 35.1%, P = 0.044). The relapse- and disease-free survival rates did not differ significantly between the groups. Our results showed that compared with UCBT, unmanipulated haplo-HSCT can improve the outcomes of children with hematologic malignances.

• 出版日期2014-8
• 单位北京大学